Tango Therapeutics (TNGX)
Develops MTAP-selective PRMT5 inhibitors for genetically defined cancers.
$24.41
vs last close+2.08 (+9.31%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 125.12% | 210.96M shares | |
|---|---|---|---|
| 259 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 12.90% | 21.76M shares | |
| 14 holders · as of Sep 3, 2026 | |||
| Strategic holders | 6.88% | 11.60M shares | |
| 1 holder · as of May 15, 2026 | |||
| Adds to | 144.90% | ||
168.61M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 144.90%; nothing is left for Other.
13F, as of Jun 30, 2026
259 holders · 210.96M shares · 81 new positions · 183 increased · 55 reduced · 24 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 13.90M | 8.24% | +600.0K | Aug 14, 2026 |
| BlackRock, Inc. | 12.44M | 7.38% | +3.69M | Aug 7, 2026 |
| FMR LLC | 12.33M | 7.31% | +2.43M | Aug 13, 2026 |
| Farallon Capital Management LLC | 12.28M | 7.28% | +3.18M | Aug 14, 2026 |
| Boxer Capital Management, LLC | 10.88M | 6.45% | 0 | Aug 14, 2026 |
| Goldman Sachs Group Inc | 9.98M | 5.92% | +4.90M | Aug 14, 2026 |
| TCG Crossover Management, LLC | 9.08M | 5.39% | −1.45M | Aug 14, 2026 |
| TRV GP Iv, LLC | 6.37M | 3.78% | 0 | Aug 10, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Davis Aaron I.incl. BCTG Holdings, LLC, MVA Investors, LLC +1 more | 10.00% | 10.74M | 13D | Jan 2, 2025 |
| TCG Crossover GP II, L.P. | 9.99% | 13.52M | 13G | Feb 17, 2026 |
| RTW Investments, LP | 9.30% | 13.30M | 13G | May 15, 2026 |
| Adage Capital Management, L.P. | 8.98% | 12.81M | 13G | May 13, 2026 |
| TCG Crossover GP II, LLC | 8.10% | 11.60M | 13G | May 15, 2026 |
| FMR LLC | 6.90% | 9.91M | 13G | May 6, 2026 |
| BlackRock, Inc. | 6.30% | 8.48M | 13G | Jan 21, 2026 |
| The Goldman Sachs Group, Inc. | 6.00% | 9.74M | 13G | Aug 14, 2026 |
| Woodline Partners LP | 5.60% | 8.00M | 13G | May 15, 2026 |
| Nextech Crossover I GP S.a. r.l. | 5.10% | 7.27M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 1, 2026 | Adam Crystalofficer: President, R&D | Sale | 27,000 | $22.37 | 115,743 |
| Aug 3, 2026 | Adam Crystalofficer: President, R&D | Sale · 2 lots | 27,000 | $27.24 | 115,743 |
| Jul 1, 2026 | Adam Crystalofficer: President, R&D | Sale · 2 lots | 27,000 | $29.59 | 115,743 |
| Jun 1, 2026 | Adam Crystalofficer: President, R&D | Sale · 2 lots | 27,000 | $22.87 | 115,743 |
| May 1, 2026 | Adam Crystalofficer: President, R&D | Sale · 2 lots | 27,000 | $21.23 | 115,743 |
| Apr 15, 2026 | Adam Crystalofficer: President, R&D | Sale | 38,460 | $25.00 | 112,622 |
| Apr 1, 2026 | Adam Crystalofficer: President, R&D | Sale | 27,000 | $21.20 | 112,622 |
| Mar 25, 2026 | Adam Crystalofficer: President, R&D | Sale | 12,000 | $20.11 | 112,622 |
| Mar 5, 2026 | Adam Crystalofficer: President, R&D | Sale | 20,251 | $15.00 | 112,622 |
| Feb 25, 2026 | Adam Crystalofficer: President, R&D | Sale | 54,345 | $12.77 | 132,873 |
House and Senate disclosures
Not reported.